Sila Attia Research Report

Patient Name: Sila Attia
Prepared on May 22, 2026

Topics

Clinical History and Chronological Progression

The clinical progression of Sila Khaled Attia, a 13.5-year-old female born on October 14, 2012, to consanguineous first-cousin parents, illustrates a complex diagnostic and therapeutic trajectory.[1] Her baseline development was entirely normal until August 2022, when she presented at age nine with a progressive gait abnormality.[1] By October 2022, her condition deteriorated rapidly to include bilateral visual impairment and ascending motor deficits.[1] Initial magnetic resonance imaging (MRI) of the brain and spine demonstrated multifocal signal alterations within the midbrain tectum, periaqueductal gray, pons, and area postrema, alongside a severe longitudinally extensive transverse myelitis (LETM) extending from C_1 to C_7.[1] Concurrently, visual evoked potentials (VEP) documented profound bilateral optic pathway delays.[1] This imaging and electrophysiological pattern closely matched the diagnostic criteria for aquaporin-4 (AQP4) seropositive neuromyelitis optica spectrum disorder (NMOSD).[1]

The patient was admitted to the pediatric intensive care unit (PICU) in November 2022 following complete quadriplegia, complete amaurosis, and acute respiratory failure requiring mechanical ventilation.[1] Believing the etiology to be autoimmune demyelination, the clinical team administered high-dose intravenous pulse corticosteroids, intravenous immunoglobulins (IVIG), and multiple cycles of therapeutic plasmapheresis.[1] Due to a lack of clinical response, a secondary diagnosis of hemophagocytic lymphohistiocytosis (HLH) was proposed, prompting the administration of two doses of rituximab in late November 2022, followed by a third dose of rituximab and IVIG on December 26, 2022, post-PICU discharge.[1] This aggressive immunomodulation failed to produce clinical or electrophysiological improvement.[1]

On December 28, 2022, blood was drawn for solo whole-exome sequencing (WES) via CentoXome MOx.[1] The results, returned on January 3, 2023, revealed no clinically relevant primary pathogenic mutations but identified a homozygous missense variant of uncertain significance (VUS) in the *BTD* gene ($c.520A >$, p.Asn174Asp).[1] This prompted a quantitative plasma biotinidase enzyme assay on January 8, 2023, which revealed a profoundly deficient activity of $0.31\ \mathrm{nmol/mL/min}$ against a normal reference range of $5.3–12.2\ \mathrm{nmol/mL/min}$.[1] This enzymatic level, being less than 10% of the mean normal serum activity, established a definitive biochemical diagnosis of profound, late-onset biotinidase deficiency and confirmed the pathogenic nature of the homozygous *BTD* VUS.[1]

The initiation of oral free biotin capsules in January 2023 at $20\ \mathrm{mg/day}$ marked the beginning of a slow but steady recovery.[1] Biotin was titrated sequentially to $40\ \mathrm{mg/day}$, $80\ \mathrm{mg/day}$, and $100\ \mathrm{mg/day}$ by June 2023.[1] At her first comprehensive neuro-genetics evaluation in April 2023, Sila was cachectic, with rough, scanty hair, severe flaccid quadriparesis, generalized hypotonia, brisk deep tendon reflexes, loss of sensation below the mid-knee level, and complete urinary and fecal incontinence, though her vision was fully restored.[1] By June 2023, sensation had returned to her arms and upper feet, and she was able to sit with support for several minutes.[1] A brief trial of intramuscular biotin yielded no additional clinical benefit, and her oral maintenance dose was stabilized at $100\ \mathrm{mg/day}$.[1]

In October 2023, despite continued sensory improvement and emerging deep touch awareness, her clinical picture was complicated by reactive depression, food refusal, severe lower-limb spasticity, progressive rightward dorsolumbar scoliosis, and the development of severe decubitus ulcers.[1] In response, oral baclofen was initiated and titrated, a spinal brace was fabricated, and local wound management was optimized.[1] In January 2024, follow-up neuroimaging demonstrated substantial regression of the brainstem and cervical

spinal cord swelling, with only faint residual periaqueductal signaling and a thin linear tract at the craniocervical junction, though a new, de-novo T2-hyperintense focal lesion emerged at the D_3 thoracic level.[1] Visual evoked potentials confirmed marked recovery, with conduction delays improving from severe to moderate.[1]

To address persistent lower-limb spasticity, her biotin dose was escalated to $200\ \mathrm{mg/day}$ and then to $300\ \mathrm{mg/day}$, baclofen was titrated upward, tizanidine (Sirdalud) was added, and she was referred to pediatric surgery for her worsening bed sores.[1] By May 2024, she had regained touch and pressure sensation in her toes and soles, her scoliosis had improved, her bed sores had completely healed, and she was able to stand with maximum support using orthotic braces.[1] At her evaluation in October 2024, her upper extremity motor strength had fully normalized, she could sit from a supine position independently, and she could stand supported for extended periods, though severe lower-limb spasticity and neurogenic bladder and bowel dysfunction remained.[1] A dual-energy X-ray absorptiometry (DEXA) scan performed at that time confirmed pediatric osteoporosis, prompting plans for intravenous bisphosphonate therapy.[1] A remote second opinion from Boston Children's Hospital in June 2025 concurred with the primary diagnosis of profound biotinidase deficiency but flagged the severity of the osteoporosis at age 12 and her exceptionally high biotin requirement as atypical features warranting further genetic investigation.[1]

Date	Biotin Dose	Motor and Sensory Status	Sphincter and Autonomic Function	Neuroimaging and Electrophysiology	Secondary Comorbidities and Interventions
Aug 2022 [1]	$0\ \mathrm{mg/day}$	Abnormal gait, progressive worsening.[1]	Intact	Baseline	None [1]
Oct 2022 [1]	$0\ \mathrm{mg/day}$	Bilateral vision loss, rapid ascending weakness.[1]	Sensation loss to mid-thigh	LETM (C_1–C_7), brainstem demyelination, severe VEP delay.[1]	Referred to neurology; initial workup.[1]
Nov 2022 [1]	$0\ \mathrm{mg/day}$	Complete flaccid quadriplegia.[1]	Complete urinary/fecal incontinence	Active demyelination with restriction on MRI.[1]	PICU admission, mechanical ventilation, pulse steroids, IVIG, plasmapheresis, 2 doses of Rituximab.[1]

Dec 2022 [1]	$0\ \mathrm{mg/day}$	Paralyzed, blind, ventilator-dependent.[1]	Incontinence	stable brainstem/cervical cord swelling	Discharged Dec 14; 3rd dose of Rituximab and IVIG on Dec 26.[1]
Jan 2023 [1]	$20–40\ \mathrm{mg/d}$	Transitioning to flaccid paraplegia.[1]	Incontinence	BTD enzyme level confirmed at $0.31\ \mathrm{nmol/mL/}$.[1]	CentoXome WES solo returned homozygous *BTD* VUS.[1]
Apr 2023 [1]	$80\ \mathrm{mg/day}$	Regained vision; severe upper and lower limb weakness; hypotonia.[1]	Incontinence; no sensation of urine or stool.[1]	VEP shows restoration of visual pathways [1]	Cachexia, rough scanty hair, hyperreflexia; physical and nutritional rehab started.[1]
Jun 2023 [1]	$100\ \mathrm{mg/day}$	Arm strength improving; sensation returned to feet; sits with support briefly.[1]	Feels urine touching skin; lacks internal sphincter control.[1]	—	Trial of intramuscular biotin (discontinued due to lack of added efficacy).[1]
Oct 2023 [1]	$100\ \mathrm{mg/day}$	Deep sensation improving; sits up from supine; lower extremity spasticity.[1]	Partial awareness of abdominal fullness/urine.[1]	—	Severe reactive depression, food refusal, rightward scoliosis, bed sores; started Baclofen and bracing.[1]
Jan 2024 [1]	$200–300\ \mathrm{mg}$	Normal upper limb strength; lower limbs highly spastic; maintains leg position 30s.[1]	Persistent incontinence	MRI: regression of brainstem and cervical swelling; new focal D_3 thoracic T2 lesion. VEP: moderate delay.[1]	Bed sores worsened; referred to pediatric surgery; increased Baclofen, added Tizanidine.[1]
May 2024 [1]	$300\ \mathrm{mg/day}$	Stand with maximum support and braces; feels pressure in toes/soles.[1]	Stable incontinence	—	Scoliosis and bed sores showing marked improvement.[1]

Oct 2024 [1]	$300\ \mathrm{mg/day}$	Stands supported long; sits supine unaided; raise back in supine; upper limbs normal.[1]	Improving sensory awareness of bowel/bladder	—	Bed sores completely healed; scoliosis resolved; DEXA confirms secondary osteoporosis.[1]
Jun 2025 [1]	$300\ \mathrm{mg/day}$	Sits independently; stands supported; persistent lower-limb spasticity.[1]	Persistent neurogenic bladder and bowel.[1]	Stable cranio-spinal MRI	BCH remote second opinion; recommended for trio exome, bone workup, and urodynamics.[1]

Pathogenesis and Genomic Architecture of Biotinidase Deficiency

Biotinidase deficiency is an autosomal recessive inborn error of biotin metabolism caused by mutations in the *BTD* gene located on chromosome 3p25.[2] Biotin (vitamin B_7 or vitamin H) serves as an obligate coenzyme for five crucial carboxylases in human tissue: pyruvate carboxylase (PC), propionyl-CoA carboxylase (PCC), 3-methylcrotonyl-CoA carboxylase (3-MCC), and the mitochondrial and cytosolic isoforms of acetyl-CoA carboxylase (ACC-1 and ACC-2).[1] These enzymes are essential for gluconeogenesis, fatty acid synthesis, and amino acid catabolism.[1] Dietary biotin is primarily consumed in a protein-bound form and must be freed to be utilized.[1] Holocarboxylase synthetase covalently attaches free biotin to a specific lysine residue on apocarboxylases to generate active holocarboxylases.[1]

During normal protein turnover, the degradation of these holocarboxylases yields biocytin (biotinyl-lysine) or small biotinylated peptides.[3] Biotinidase is responsible for cleaving these biocytin molecules, releasing free, non-protein-bound biotin that is recycled back into the cellular pool.[2] In the absence of functional biotinidase activity, biocytin cannot be cleaved; it is lost in the urine, leading to rapid depletion of systemic biotin stores.[1] This secondary, absolute deficiency of free biotin impairs the activity of all five biotin-dependent carboxylases, culminating in multiple carboxylase deficiency.[4]

The metabolic consequences of this multi-carboxylase block are extensive and generate toxic systemic metabolites.[3] Pyruvate carboxylase dysfunction prevents the conversion of pyruvate to oxaloacetate, disrupting the citric acid cycle and gluconeogenesis, which drives the accumulation of pyruvate and its conversion into lactate, causing severe lactic acidosis.[1] Propionyl-CoA carboxylase failure blocks the pathway of odd-chain fatty acids, cholesterol side chains, and the amino acids isoleucine, valine, methionine, and threonine into succinyl-CoA.[1] This leads to the accumulation of propionyl-CoA, which is diverted into propionylcarnitine (C_3), 3-hydroxypropionic acid, and methylcitrate.[1]

Dysfunction of 3-methylcrotonyl-CoA carboxylase impairs leucine catabolism, causing an accumulation of 3-methylcrotonyl-CoA, which is metabolized by enoyl-CoA hydratase into 3-hydroxyisovaleryl-CoA, subsequently yielding 3-hydroxyisovaleric acid (commonly measured as a marker of cellular biotin depletion) and 3-methylcrotonylglycine.[1] Finally, acetyl-CoA carboxylase deficiency restricts the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in cytosolic fatty acid synthesis.[1] This impairs the synthesis of long-chain fatty acids required for myelin sheath maintenance, directly contributing to the progressive demyelinating spinal cord disease, area postrema syndrome, and optic neuropathy observed in Sila's late-onset presentation.[1]

Carboxylase Enzyme	Cytological Location	Principal Metabolic Pathway	Substrate to Product Reaction	Accumulating Toxic Metabolites	Clinical Consequences of Deficiency
Pyruvate Carboxylase (PC) [1]	Mitochondrial matrix [1]	Gluconeogenesis; replenishes citric acid cycle intermediates.[1]	Pyruvate to Oxaloacetate [1]	Pyruvate, Lactic acid, Alanine [4]	Lactic acidosis, hypoglycemia, ketosis, developmental delay, and severe hypotonia.[4]
Propionyl-CoA Carboxylase (PCC) [1]	Mitochondrial matrix [1]	Catabolism of odd-chain fatty acids, valine, isoleucine, methionine, threonine.[6]	Propionyl-CoA to Methylmalonyl-CoA [1]	Propionyl-CoA, Propionylcarnitine (C_3), 3-Hydroxypropionic acid, Methylcitrate.[1]	Metabolic ketoacidosis, hyperammonemia, developmental regression, and cardiomyopathy.[4]
3-Methylcrotonyl-CoA Carboxylase (3-MCC) [1]	Mitochondrial matrix [1]	Essential pathway for Leucine amino acid catabolism.[1]	3-Methylcrotonyl-CoA to 3-Methylglutaconyl-CoA [1]	3-Methylcrotonyl-CoA, 3-Hydroxyisovaleric acid, 3-Methylcrotonylglycine.[1]	Neurological deterioration, alopecia, dermatitis, and developmental delay.[2]
Acetyl-CoA Carboxylase 1 (ACC-1) [1]	Cytosol [1]	De-novo synthesis of long-chain fatty acids.[1]	Acetyl-CoA to Malonyl-CoA [1]	Acetyl-CoA, Malonic acid	Impaired myelin lipid synthesis, white matter demyelination, and axonal degeneration.[1]
Acetyl-CoA Carboxylase 2 (ACC-2) [1]	Outer mitochondrial membrane [1]	Regulation of mitochondrial beta-oxidation of fatty acids.[1]	Acetyl-CoA to Malonyl-CoA [1]	Acetyl-CoA	Muscle weakness, systemic hypotonia, and chronic fatigue.[4]

Advanced Differential Diagnostic Framework and Clinical Tiers

To clinical peers, Sila's diagnostic assessment requires stratification into primary, secondary/comorbid, and rule-out tiers to structure her ongoing management safely.[1] This diagnostic framework accounts for genetic, biochemical, and imaging data while addressing anomalous features of her clinical recovery.[1]

Tier 1: Primary Diagnoses (High Probability and Biochemically Definitive)

The foremost diagnosis is profound, late-onset biotinidase deficiency presenting as an atypical demyelinating longitudinally extensive transverse myelitis (LETM) with bilateral optic neuropathy, mimicking neuromyelitis optica spectrum disorder (NMOSD).[1] Profound biotinidase deficiency is defined by a serum enzyme activity $< 10\%$ of the mean normal level.[7] Sila's level of $0.31\ \mathrm{nmol/mL/mi}$ represents approximately 3.5% of the mean normal, confirming profound deficiency.[1] The incidence of profound deficiency is approximately 1 in 137,401 births.[7] Late-onset presentations (appearing from infancy up to 10 years of age, with some adult cases documented) can manifest with atypical neurological symptoms, including progressive spastic paraparesis, optic neuropathy, and spinal cord lesions.[2] Sila's homozygous sequence variant ($c.520A >$, p.Asn174Asp) represents a pathogenic mutation when paired with this diagnostic enzymatic level, resolving its initial VUS classification.[1]

The secondary diagnosis within Tier 1 is chronic, non-progressive myelopathy secondary to the original $C_1–C_7$ spinal cord injury.[1] While the biochemical block has been resolved with biotin, the extensive initial demyelination and axonal damage of the cervical cord have left permanent structural sequelae.[1] This damage explains her persistent upper motor neuron spasticity, hyperreflexia, and neurogenic bladder and bowel dysfunction.[1]

The third diagnosis is neuromuscular scoliosis, which developed secondary to trunk muscle hypotonia and prolonged immobilization, and has shown significant improvement with custom orthotic bracing.[1]

Tier 2: Secondary and Comorbid Conditions (Moderate Probability)

The most prominent comorbid condition is pediatric secondary osteoporosis, confirmed by a DEXA scan in October 2024.[1] The pathogenesis is highly multifactorial, driven by prolonged physical non-weight-bearing states, the osteotoxic effect of high-dose corticosteroids administered during her misdiagnosis phase, and chronic protein-calorie malnutrition with documented food refusal.[1]

However, as flagged by Dr. Melinda Peters of Boston Children's Hospital, the development of osteoporosis severe enough to warrant bisphosphonate therapy in a 12-year-old female who has partially regained her vision and motor strength is atypical.[1] This raises the probability of a co-segregating secondary monogenic bone-fragility or metabolic disorder.[1] Because Sila is the offspring of a first-cousin consanguineous marriage, the coefficient of inbreeding is significantly elevated, dramatically raising the prior probability of homozygous recessive mutations at multiple independent loci.[1]

Other Tier 2 diagnoses include neurogenic bladder and bowel dysfunction, reactive clinical depression, and chronic protein-calorie malnutrition.[1]

Tier 3: Critical Rule-Outs (Lower Probability, High-Stakes)

The most critical rule-out is coexisting seropositive NMOSD (AQP4-IgG+) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD, MOG-IgG+).[1] Sila's initial presentation with a $C_1–C_7$

LETM, area postrema syndrome, and optic neuropathy is the classic signature of AQP4-positive NMOSD.[1] Although she showed dramatic improvement on biotin, the emergence of a new, de-novo T2-hyperintense focal lesion at the D_3 thoracic level in her January 2024 MRI—in the absence of documented baseline or follow-up AQP4-IgG and MOG-IgG antibody titers—warrants definitive exclusion.[1] If she possesses a coexisting, antibody-mediated relapsing demyelinating disease alongside her biotinidase deficiency, she remains at risk for further inflammatory attacks that require maintenance disease-modifying immunotherapies (e.g., rituximab, satralizumab, or inebilizumab), which are entirely distinct from metabolic biotin therapy.[1]

Other metabolic and nutritional spinal cord mimics, such as biotin-thiamine-responsive basal ganglia disease (*SLC19A3* mutations), holocarboxylase synthetase deficiency, and subacute combined degeneration of the spinal cord secondary to vitamin B12 or copper deficiency, must also be systematically excluded.[1]

Tier	Diagnostic Category	Specific Condition	Pathophysiological Basis & Supporting Data	Required Diagnostic Investigation for Confirmation
Tier 1 [1]	Primary [1]	Profound late-onset Biotinidase Deficiency [1]	Homozygous missense *BTD* variant ($c.520A >$).[1] Serum enzyme activity of $0.31\ \mathrm{nmol/mL/m}$.[1] Rapid clinical and visual recovery on biotin.[1]	Already biochemically confirmed; molecular validation complete.[1]
	Primary [1]	Chronic Myelopathy [1]	Permanent cervical cord injury (C_1–C_7 LETM) with persistent lower-limb spasticity, hyperreflexia, and neurogenic bladder/bowel.[1]	Follow-up high-resolution MRI of the spine with and without gadolinium.[1]
	Primary [1]	Neuromuscular Scoliosis [1]	Asymmetric paraspinal muscle weakness and trunk hypotonia during prolonged immobilization.[1]	Standing scoliosis X-ray series with Cobb angle measurements.[1]

Tier 2 [1]	Comorbid / Secondary [1]	Secondary Pediatric Osteoporosis [1]	Confirmed on DEXA.[1] Driven by immobilization, glucocorticoid exposure, and severe protein-calorie malnutrition.[1]	Baseline bone turnover markers, PTH, 25-hydroxyvitamin D, and lateral spine X-rays.[10]
	Comorbid / Secondary [1]	Secondary Monogenic Bone-Fragility Disorder [1]	Dr. Melinda Peters' flag: severe osteoporosis at age 12 is highly atypical; elevated risk of dual homozygous mutations due to first-cousin consanguinity.[1]	Trio whole-exome or whole-genome sequencing (patient and parents).[1]
	Comorbid / Secondary [1]	Reactive Depression and Malnutrition [1]	Documented clinical depression, food refusal, and cachectic baseline.[1]	Clinical psychological scoring; dietary assessment and pre-albumin tracking.[1]
Tier 3 [1]	Rule-Outs [1]	Coexisting Seropositive NMOSD or MOGAD [1]	Classic LETM, optic nerve, and brainstem lesions.[1] New D_3 thoracic cord lesion in Jan 2024 despite high-dose biotin.[1]	Serum AQP4-IgG and MOG-IgG antibodies via live cell-based assay (LCBA-FACS).[15]
	Rule-Outs [1]	Other Neurometaboli c Mimics [1]	Clinical symptoms overlap with thiamine-transport defects and holocarboxylase synthetase deficiency.[1]	Urine organic acids and plasma acylcarnitine profile via GC-MS and LC-MS/MS.[1]

Investigation and Mitigation Protocol for Biotin Laboratory Interference

Mechanism and Pharmacokinetics of Biotin Interference

Therapeutic administration of biotin at a mega-dose of $300\ \text{mg/day}$ creates a profound safety hazard in clinical diagnostics.[16] Modern clinical laboratories heavily rely on the extremely robust, non-covalent streptavidin-biotin affinity system ($K_d \approx 10^{-15}\ \text{M}$) to separate antibody-analyte complexes from serum matrices.[18] Free biotin in the patient's blood sample competitive binds to streptavidin-coated solid phases (e.g., magnetic microparticles or beads), blocking the binding of biotinylated capture antibodies or antigens.[16] This biochemical competition leads to two highly misleading, systematic analytical errors:

- **Non-Competitive (Sandwich) Immunoassays:** Utilized for large protein analytes including Thyroid-Stimulating Hormone (TSH), Parathyroid Hormone (PTH), beta-Human Chorionic Gonadotropin (beta-hCG), Ferritin, and cardiac Troponin.[17] In this assay, the measured signal is directly proportional to the analyte concentration.[17] Excess free biotin saturates the streptavidin solid phase, preventing the capture of the antibody-analyte-antibody sandwich.[16] The analyte complex is subsequently washed away during the assay cycle, resulting in a **falsely decreased/low** result.[16]
- **Competitive Immunoassays:** Utilized for small molecule analytes including Free Thyroxine (FT_4), Free Triiodothyronine (FT_3), total thyroid hormones, Cortisol, Testosterone, Estrogen, Progesterone, and 25-hydroxyvitamin D.[17] In this assay, the measured signal is inversely proportional to the analyte concentration.[16] Excess free biotin saturates the streptavidin solid phase, blocking the binding of labeled competitive analogs.[16] This generates an artificially low signal, resulting in a **falsely elevated/high** result.[16]

At Sila's mega-dose of $300\ \text{mg/day}$, her serum biotin concentrations are highly elevated.[17] The thyroid panel, for instance, can present a classic but false profile of severe hyperthyroidism (Graves' disease) characterized by an untraceable, falsely low TSH and falsely high FT_4 and FT_3.[18] Furthermore, biotin also interferes with the detection of anti-thyrotropin receptor antibodies, which can result in a false-positive laboratory pattern identical to Graves' disease.[18] Falsely low troponin levels can delay the diagnosis of myocardial strain, and falsely low beta-hCG can mask systemic pathology.[20]

Normal circulating biotin derived from standard dietary intake typically ranges from $0.1\ \text{to}\ 0.8\ \text{ng/mL}$, which is far below the interference thresholds of commercial assays.[17] Biotin is rapidly absorbed, reaching peak plasma concentration within 1 to 2 hours post-ingestion.[17] At standard physiological and multivitamin doses ($\leq 1\ \text{mg}$), the elimination half-life is approximately 2 hours.[17] However, at pharmacological and mega-doses ($100\text{–}300\ \text{mg}$), the elimination half-life extends up to 18.8 hours due to the saturation of renal clearance thresholds.[17] In healthy individuals, plasma biotin concentrations require 146 hours (approximately 6 days) to drop below $20\ \text{ng/mL}$ (the common threshold of analytical interference for Roche and Beckman platforms) following a single $300\ \text{mg}$ oral dose, with clearance further delayed in patients with subclinical

renal impairment.[17]

Analyte	Immunoassay Design	Susceptibility to Biotin	Direction of Analytical Bias	Clinical Consequences & Misdiagnosis Risks
Thyroid-Stimulating Hormone (TSH) [18]	Non-competitive (Sandwich) [18]	Highly susceptible on Roche & Beckman platforms.[23]	Falsely decreased (Low) [18]	Misdiagnosis of primary or subclinical hyperthyroidism (Graves' disease), leading to unnecessary anti-thyroid drug initiation.[18]
Free Thyroxine (FT_4) / Free Triiodothyronine (FT_3) [18]	Competitive [18]	Highly susceptible on Roche & Beckman platforms.[23]	Falsely elevated (High) [18]	Reinforces false Graves' profile; masks secondary hypothyroidism.[18]
Parathyroid Hormone (PTH) [18]	Non-competitive (Sandwich) [18]	Highly susceptible.[18]	Falsely decreased (Low) [18]	Misdiagnosis of hypoparathyroidism; fails to detect secondary hyperparathyroidism in chronic osteoporosis.[18]
25-Hydroxyvitamin D [18]	Competitive [18]	Highly susceptible.[18]	Falsely elevated (High) [18]	Overestimates vitamin D adequacy; masks active osteomalacia and delays vitamin D replacement in osteoporosis.[14]
Cardiac Troponins (I and T) [20]	Non-competitive (Sandwich) [20]	Highly susceptible.[20]	Falsely decreased (Low) [20]	Missed or delayed diagnosis of myocardial strain or silent ischemia.[20]
Ferritin [18]	Non-competitive (Sandwich) [18]	Susceptible.[18]	Falsely decreased (Low) [18]	Misdiagnosis of iron-deficiency anemia.[20]

Cortisol [20]	Competitive [20]	Susceptible.[20]	Falsely elevated (High) [20]	Falsely suggests Cushing's syndrome or adrenal hyperfunction.[20]
AQP4-IgG and MOG-IgG Antibodies [15]	Live Cell-Based Assay (LCBA-FACS) [15]	Minimal to none, depending on secondary reagent design.[27]	Falsely decreased (Low) if secondary detection is biotinylated.	Underrecognition of comorbid NMOSD/MOGAD; delays essential immunosuppressive initiation.[1]

Clinical Action Plan for Lab Assays and Washing-Out

To mitigate these diagnostic risks while protecting Sila from metabolic decompensation, the clinical team must implement a structured, pre-analytical, and analytical protocol [1]:

- **Analytical Platform Selection:** For routine labs (TSH, FT_4, FT_3, PTH, troponin, ferritin, cortisol), Sila's samples should be routed exclusively to platforms that do not utilize the biotin-streptavidin separation chemistry in their assay designs, such as the Abbott Architect platform, or alternative methodologies like Liquid Chromatography-Mass Spectrometry (LC-MS/MS).[21]
- **Pre-Analytical Biotin Depletion:** If biotin-susceptible assays are unavoidable, the laboratory must perform pre-analytical biotin-depletion protocols.[16] This involves treating the patient's serum with streptavidin-coated agarose beads or silica particles to bind and pull down the excess free biotin from the serum sample prior to running the immunoassay.[16]
- **Monitored Washout Protocol for Critical Diagnostics:** For high-stakes diagnostic assays that are highly sensitive to biotin and require native serum (such as specific cell-based assays for AQP4-IgG and MOG-IgG), a controlled washout is required.[1] Because Sila has profound biotinidase deficiency, a full 7-day outpatient hold is clinically contraindicated due to the high risk of acute, life-threatening metabolic relapses.[1] The patient should be admitted to a monitored inpatient setting.[1] Biotin may be safely held for a maximum of $72–96\ \text{hours}$ (allowing serum biotin concentrations to drop below most assay interference thresholds while the patient remains clinically stable on a strictly controlled, carbohydrate-rich diet to prevent catabolism).[17] Blood must be drawn immediately at the end of this window, and her mega-dose of $300\ \text{mg/day}$ biotin must be re-administered intravenously or orally on the ward.[1]

Pediatric Osteoporosis Management and Bisphosphonate Safety Protocol

DEXA Interpretation and Diagnostic Criteria

Pediatric osteoporosis is diagnosed differently than the adult form.[30] In children, a low bone mineral density (BMD) or bone mineral content (BMC) is defined by an areal BMD Z-score that is less than or equal to -2.0, adjusted strictly for age, biological sex, and height-matched norms.[10]

A diagnosis of pediatric osteoporosis requires the presence of [10]:

- At least one low-trauma vertebral compression fracture, in the absence of local spinal disease or high-energy trauma.[10] In this scenario, a DEXA scan is supportive but not strictly mandatory to establish the diagnosis.[10]
- Or, the combination of a clinically significant fracture history—defined as two or more low-trauma long-bone fractures by age 10 years, or three or more by age 19 years—and a DEXA lumbar spine or total-body-less-head (TBLH) BMD Z-score ≤ -2.0.[10]

Sila's October 2024 DEXA scan documented osteoporosis in the context of her prolonged physical non-weight-bearing states and severe paraspinal muscle hypotonia.[1]

Pre-Treatment Biochemical Evaluation and Screening

Prior to the administration of any intravenous bisphosphonate, the patient must undergo a rigorous, standardized pre-treatment metabolic workup to ensure clinical safety and rule out underlying osteomalacia or rickets [14]:

- **Metabolic Screen:** Serum calcium, phosphate, albumin (to calculate albumin-corrected calcium), creatinine, alkaline phosphatase (ALP, verifying it is within normal limits for age to exclude hypophosphatasia), intact Parathyroid Hormone (PTH), and 25-hydroxyvitamin D.[14]
- **Renal Function:** Estimation of glomerular filtration rate (eGFR). Intravenous bisphosphonates are strictly contraindicated in patients with severe renal impairment (creatinine clearance $< 30\ \text{mL/min/1.73m}^2$ for pamidronate or $< 35\ \text{mL/min}$ for zoledronate).[33]
- **Pregnancy Screening:** A mandatory serum pregnancy test is required for teenage female patients, as bisphosphonates are retained in the skeletal matrix for years, can cross the placenta during future pregnancies, and present theoretical risks of fetal skeletal abnormalities and hypocalcemia.[30]
- **Dental Evaluation:** A comprehensive dental examination and treatment of any active caries or dental abscesses must be completed, with complete healing achieved before drug administration, to mitigate the risk of osteonecrosis of the jaw.[33]

Bisphosphonate Dosing, Preparation, and Calcium/Vitamin D Priming

The two primary intravenous bisphosphonates utilized in pediatric metabolic bone clinics are cyclic pamidronate and zoledronic acid (zoledronate).[35] Zoledronic acid has largely replaced pamidronate as the preferred first-line agent in modern pediatric endocrine centers due to its significantly higher potency, shorter infusion duration, and longer dosing intervals.[37]

To prevent severe, symptomatic post-infusion hypocalcemia and tetany, a strict pre-infusion priming protocol must be followed [33]:

- **Pre-Infusion Priming:** The patient must begin oral elemental calcium supplementation ($50\ \mathrm{mg/kg/day}$ of elemental calcium, up to a maximum of $2500\ \mathrm{mg/day}$) and oral vitamin D (cholecalciferol) $3\ \text{to}\ 14\ \mathrm{days}$ prior to the scheduled infusion.[33] Calvive effervescent tablets or calcium syrup must be commenced 3 days pre-infusion and continued for 7 days post-infusion.[33]
- **Hydration:** The patient must be well hydrated before the infusion, and co-administration of aminoglycoside antibiotics must be avoided.[33]

For zoledronic acid, the standard pediatric dosing regimen is highly structured [37]:

- **First Infusion:** A conservative dose of $0.0125\ \mathrm{mg/kg}$ (maximum $0.5–1.0\ \mathrm{mg}$) is administered intravenously over at least 30 minutes, to minimize the severity of the first-dose acute-phase reaction.[37]
- **Second Infusion:** Administered at $0.0375\ \mathrm{mg/kg}$ (maximum $1.0\ \mathrm{mg}$) at $6\ \text{to}\ 8\ \mathrm{weeks}$ post-first dose (ensuring the cumulative dose of the first two infusions equals $0.05\ \mathrm{mg/kg}$).[37]
- **Subsequent Infusions:** Administered at $0.05\ \mathrm{mg/kg}$ (maximum $2.0\ \mathrm{mg}$) every $6\ \mathrm{months}$.[37]

For pamidronate, the cyclic regimen is [33]:

- Administered at $1.0\ \mathrm{mg/kg/day}$ (up to $3.0\ \mathrm{mg/kg/cycle}$) over 4 hours for 3 consecutive days every 3 to 4 months.[33] The maximum annual cumulative dose should not exceed $12\ \mathrm{mg/kg}$.[33]

Safety Profiles and Long-Term Surveillance

- **Acute-Phase Reaction:** The most common adverse effect, occurring in up to 80% of pediatric patients within 1 to 3 days of the first infusion.[30] It presents with high fever, headache, myalgias, arthralgias, bone pain, and nausea, and is typically transient, resolving within 3 days.[30] It is managed with scheduled acetaminophen or ibuprofen.[35] Subsequent infusions are significantly better tolerated.[35]
- **Electrolyte Derangements:** Hypocalcemia, hypophosphatemia, and hypomagnesemia.[30] Serum calcium and albumin must be checked $24\ \text{to}\ 48\ \mathrm{hours}$ after the first infusion.[37] If corrected calcium falls below $2.1\ \mathrm{mmol/L}$, calcium supplements must be increased.[33]
- **Ophthalmic & Serious Risks:** Rare pediatric cases of uveitis, scleritis, and thrombocytopenia have been reported.[30] Osteonecrosis of the jaw and atypical femoral fractures are serious risks in adults but are extremely rare in pediatric cohorts.[30]
- **Linear Growth and Modeling:** Bisphosphonates do not impair linear bone growth, trabecular bone formation, or periosteal modeling in children.[31] They reduce bone resorption while ongoing growth and modeling significantly increase cortical width and trabecular density, improving overall bone strength.[31]
- **Long-Term Matrix Retention:** Nitrogen-containing bisphosphonates bind with high affinity to bone mineral and are retained in the skeletal matrix for years.[31] Evidence demonstrates renal excretion of bisphosphonates up to 8 years after the cessation of therapy.[31] For secondary osteoporosis, treatment is typically continued for 2 to 3 years, followed by a comprehensive re-evaluation of bone health and fracture rates.[37]

Bisphosphonate Agent	Potency Relative to Pamidronate	Standard Pediatric Dosing Protocol	Infusion Preparation and Duration	Required Pre-Infusion Priming	Post-Infusion Monitoring (24--48 hrs)	Long-Term Skeletal Retention	Primary Risks & Side Effects
Zoledronic Acid (Zoledronate) [35]	$\approx$ higher potency.[37]	**1st:** 0.0125 m **2nd:** 0.0375 m at 6-8 weeks **3rd+:** 0.05 mg/ every 6 months.[37]	Diluted in 100 mL 0.9% NaCl; infused at constant rate over $\geq$.[37]	Oral Calcium and Vitamin D starting $7–14$ days prior; stop all aminorlycosides.[33]	Check serum calcium and albumin at 48 hours post-first infusion.[37]	Highly retained; urinary excretion detected up to 8 years post-cessation.[31]	Acute-phase reaction (fever, bone pain), hypocalcemia, transient hypophosphatemia.[30]
Pamidronate [33]	1.0 (Baseline Reference) [37]	1.0 mg/k daily for 3 consecutive days every 3 to 4 months.[33]	Reconstituted with sterile water; diluted in 250 mL 0.9% NaCl; infused over $2–4$ hours .[33]	Start oral Calvive 3 days prior; ensure baseline corrected Calcium $>$.[33]	Monitor temperature and blood pressure 4-hourly on Day 1 and Day 2.[33]	Moderately retained in skeletal matrix; slow renal clearance over years.[31]	Fever, hypocalcemia, site pain, rare ocular inflammation (uveitis).[30]

Neuro-Restorative and Bladder-Modulation Strategies for Transverse Myelitis

Clemastine Fumarate as a Remyelinating Agent

Clemastine fumarate, a first-generation over-the-counter antihistamine, has been repurposed as a promyelinating agent.[39] High-throughput screening platforms identified clemastine's ability to promote the differentiation of endogenous oligodendrocyte precursor cells (OPCs) into mature, myelin-producing oligodendrocytes.[40] Clemastine acts as a potent antagonist at M1 muscarinic acetylcholine receptors (CHRM1) on OPCs.[41] This blockade activates the extracellular signal-regulated kinase (ERK) pathway, induces histone methyltransferase activity, and stimulates the glutathione S-transferase 4α (Gsta4)/4-hydroxynonenal (4-HNE) pathway, driving oligodendrocyte maturation and myelin sheath regeneration.[43] Preclinical models of compressed spinal cord injury and inflammatory demyelination (EAE) demonstrate that clemastine administration improves clinical locomotor scores, protects axonal integrity, and enhances remyelination.[39] In the landmark Phase II ReBUILD crossover trial, clemastine treatment in patients with relapsing-remitting multiple sclerosis (RRMS) met its primary efficacy endpoint, showing a small but statistically significant improvement in visual evoked potential (VEP) P100 latency, which indicates the repair of demyelinated optic pathways.[41] Ongoing trials, such as CCMR Two (evaluating metformin and clemastine) and ReVIVE (using multi-parametric MRI), continue to assess its remyelinating potential.[46]

However, a critical safety discrepancy emerged in the progressive multiple sclerosis platform trial (TRAP-MS, NCT03109288).[48] The clemastine arm was halted after 3 of 9 patients experienced a rapid acceleration of disability.[41] Researchers concluded that under certain active inflammatory or degenerative conditions, clemastine can enhance inflammatory cell damage and promote cell pyroptosis.[41] Consequently, while clemastine is a promising remyelinating agent, its use in Sila's case is contraindicated during any active, contrast-enhancing neuro-inflammatory phase and lacks established pediatric dosing guidelines.[39]

NVG-291: Axonal Regeneration and Glial Scar Permeation

NVG-291 is an investigational, first-in-class neuroreparative peptide designed to promote nervous system repair.[49] Following central nervous system trauma or myelitis, astrocytes proliferate and form a dense glial scar rich in growth-inhibiting chondroitin sulfate proteoglycans (CSPGs).[51] CSPGs bind to and activate the protein tyrosine phosphatase sigma (PTPσ) receptor on damaged axons, signaling the arrest of axonal growth and preventing remyelination.[51] NVG-291 is a peptide mimetic derived from the regulatory wedge domain of the PTPσ receptor.[50] Administered as a daily subcutaneous injection, it crosses the blood-brain barrier via a cell-penetrating tag and competitive blocks the PTPσ receptor.[52] This blockade renders the glial scar permeable, promoting axonal regeneration, sprouting, remyelination, and neuroplasticity.[51]

In preclinical models of spinal cord injury and stroke, NVG-291 promoted functional recovery, locomotion, and bladder control.[50] The Phase Ib/2a proof-of-concept CONNECT SCI trial, conducted at the Shirley Ryan AbilityLab, evaluated NVG-291 in subacute and chronic cervical spinal cord injury cohorts.[50] Among treated chronic tetraplegic patients, those receiving NVG-291 experienced a mean improvement of $+3.7$ points on the quantitative GRASSP hand-function assessment at Week 12 (compared to $+0.4$ points for placebo), which was sustained to $+4.4$ points at Week 16.[49]

Notably, real-world follow-up documented that 67% of NVG-291-treated subjects experienced improved bladder control, and 56% reported reduced muscle spasticity.[55] NervGen Pharma reached alignment with the FDA on the design of the Phase III RESTORE registrational study in chronic tetraplegia, planned for mid-2026.[49] NVG-291 represents a promising pipeline therapy for Sila's chronic lower-limb spasticity and neurogenic bladder once she meets the age criteria (currently restricted to ages $18–75$).[49]

Stem Cell Therapeutics

Stem cell therapies, utilizing bone marrow-derived mesenchymal stem cells (BMSCs) or induced pluripotent stem cells (iPSCs), offer neuroprotective and regenerative potential.[57] BMSCs, which can be harvested and expanded autologously, migrate to the site of spinal cord injury and release a cocktail of neurotrophic factors, including nerve growth factor (NGF), vascular endothelial growth factor (VEF), glial-derived neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF).[57] These factors promote cell survival, modulate local inflammation, and protect axons from secondary degeneration.[57]

Clinical trials in subacute and chronic spinal cord injury show that intravenous or intrathecal BMSC delivery is safe and correlates with improvements in the American Spinal Injury Association Impairment Scale (AIS) classification and spinal cord independence measures (SCIM III).[57] Meanwhile, iPSC technologies enable patient-specific disease modeling and are under development to generate myelinated glial progenitor cells capable of remyelinating damaged white matter tracts.[58] Stem cell interventions are currently experimental and lack standardized protocols regarding transplantation timing, cell dosage, and delivery routes.[60]

Sacral Neuromodulation (SNM) for Neurogenic Bladder & Bowel

Sacral neuromodulation (SNM, InterStim) is a minimally invasive, reversible surgical technique utilized off-label for refractory pediatric neurogenic bladder and bowel dysfunction.[61] SNM involves the surgical placement of an electrode through the S_3 neural foramen to deliver mild, continuous electrical impulses to the S_3 nerve root.[61] Rather than causing direct motor contraction, SNM modulates pelvic afferent signaling to the spinal cord and higher cortical centers, suppressing detrusor overactivity and restoring functional storage and voiding reflexes.[61]

The therapy is performed in two distinct stages: an initial percutaneous test phase utilizing an external stimulator (offering a 2-week trial where a $> 50\%$ improvement in symptoms is required), followed by the permanent subcutaneous implantation of an internal generator.[62] In pediatric cohorts with refractory lower urinary tract dysfunction, SNM achieves success rates of $61\%–73\%$ in improving continence and reducing post-void residual (PVR) volumes.[61]

Crucially, a 13-year pediatric review of 129 SNM placements documented that approximately 35.7% of patients eventually underwent device explantation.[62] Among these explantations, 73.9% were due to complete clinical symptom resolution ("cure"), with 94% of cured patients demonstrating sustained continence at a median of 3.8 years post-explantation.[62] On competing risks analysis, the 6-year pediatric risk of explantation for cure was 36.3%, compared to 13.8% for device-related complications.[62] Complications include a surgical lead revision rate of 31.8%, a low local infection rate of 4%, site pain, and potential incompatibility with spinal MRI requirements, though modern full-body MRI-approved devices have expanded

the clinical utility of SNM in neurologically complex patients.[62]

Neuro-Restorative Therapy	Molecular & Cellular Target	Primary Mechanism of Action	Intended Clinical Population	Documented Clinical Efficacy & Trial Results	Major Safety Risks & Limitations
Clemastine Fumarate [39]	M1 Muscarinic Acetylcholine Receptors (CHRM1).[41]	Matures OPCs into myelinating oligodendrocytes; activates ERK/Gsta4 pathways.[42]	Relapsing-remitting multiple sclerosis; stable optic neuropathy.[41]	**ReBUILD:** Significant reduction in VEP P100 latency (myelin repair).[41]	**TRAP-MS:** Halted due to accelerated disability and inflammatory pyroptosis.[41]
NVG-291 [49]	Protein Tyrosine Phospatase Sigma (PTPσ) Receptor.[50]	Blocks CSPG-mediated growth inhibition; promotes axonal sprouting and plastic repair.[51]	Chronic and subacute cervical spinal cord injury (tetraparesis).[50]	**CONNECT SCI:** Mean +3.7 GRASSP score improvement; 67% improved bladder control.[49]	Currently restricted to ages $18–75$; Phase III RESTORE trial pending.[49]
BMSC / iPSC Therapy [57]	Inflammatory microenvironment; local neural tissue.[57]	Secretion of neurotrophic factors (NGF, BDNF); glial cell replacement.[57]	Traumatic and demyelinating spinal cord injury.[57]	Improvement in AIS classification and SCIM III functional scales in small cohorts.[57]	Risk of local tumorigenicity, spinal instability, and lacks standardized dosing protocols.[58]
Sacral Neuromodulation (SNM) [61]	S_3 Spinal Nerve Root; pelvic afferents.[61]	Modulates spinal reflexes and cortical centers; suppresses detrusor overactivity.[61]	Refractory pediatric neurogenic bladder and bowel dysfunction.[61]	$61\%–73\%$ success; 36.3% 6-year probability of complete clinical "cure" and explant.[61]	High lead revision rate (31.8%); local infection (4%); potential MRI limitations.[62]

Prioritized Multidisciplinary Recommendations

The clinical management of Sila Khaled Attia requires immediate, strategic, and long-term diagnostic and therapeutic actions coordinated across specialties.[1]

Immediate (Short-Term) Clinical Actions

- **Uninterrupted Biotin Maintenance:** Oral free biotin must be maintained at $300\ \mathrm{mg/day}$.[1] Any interruption of this coenzyme carries an extreme risk of metabolic ketoacidosis and catastrophic neurological relapse.[1]
- **Osteoporosis Priming Protocol:** To prepare Sila for her scheduled intravenous bisphosphonate therapy, the clinical team must immediately initiate oral elemental calcium supplementation ($50\ \mathrm{mg/kg/day}$ elemental calcium) and oral cholecalciferol (vitamin D).[33] The Calvive effervescent calcium regimen (or an equivalent pediatric syrup) must be administered starting 3 days prior to her infusion and continued for 7 days post-infusion.[33]
- **Mandatory Pre-Treatment Screening:** The clinical team must obtain a baseline complete blood count, eGFR, serum calcium, phosphate, albumin, intact PTH, 25-hydroxyvitamin D, and ALP (verifying ALP is within normal age limits).[14] A serum pregnancy test is mandatory before drug administration.[33]
- **Dental and Surgical Clearance:** The patient must undergo a comprehensive dental evaluation to treat and resolve any active caries or dental infections before her first bisphosphonate infusion, to mitigate the risk of osteonecrosis of the jaw.[33]
- **Spasticity Management:** Titrate her current combination of oral baclofen and tizanidine to balance motor tone, ensuring she undergoes daily intensive physical therapy, stretching, and custom orthotic spinal and lower-limb bracing to maintain alignment and prevent contractures.[1]
- **High-Resolution Contrast Neuroimaging:** Schedule a repeat MRI of the brain and the entire spinal cord *with gadolinium contrast*.[1] Every neuroimaging study performed to date has lacked post-contrast sequences.[1] Contrast enhancement is essential to evaluate the inflammatory activity of the de-novo D_3 thoracic lesion, assess blood-spinal cord barrier integrity, and distinguish inactive gliosis from active demyelinating disease.[1]

Strategic (Medium-Term) Clinical Actions

- **Intravenous Zoledronic Acid Administration:** Following metabolic priming, dental clearance, and negative pregnancy screening, Sila should proceed with her first intravenous zoledronic acid infusion.[33] A starting dose of $0.0125\ \mathrm{mg/kg}$ is administered over 30 minutes in a monitored clinic, with scheduled acetaminophen or ibuprofen to manage the acute-phase reaction.[35] Serum calcium and albumin must be verified at $48\ \mathrm{hours}$ post-infusion to detect and manage hypocalcemia.[37]
- **Trio Whole-Exome / Genome Sequencing:** Given the parental first-cousin consanguinity, her atypical development of severe osteoporosis at age 12, and her high biotin requirement, the clinical team should coordinate with the Department of Medical Genetics at Ain Shams University to perform trio whole-exome or whole-genome sequencing (patient and parents).[1] This is essential to determine the parental segregation of her *BTD* variant and screen for a secondary, homozygous recessive gene defect causing her bone fragility.[1]
- **Live Cell-Based Assay under Controlled Biotin Hold:** To definitively rule out coexisting, antibody-

mediated demyelinating diseases (NMOSD or MOGAD) in the context of her D_3 lesion, a serum sample must be analyzed via live cell-based assay flow cytometry (LCBA-FACS) for AQP4-IgG and MOG-IgG.[15] To prevent profound biotin-induced assay interference, this draw must be coordinated with a temporary, inpatient, medically supervised $72–96\ \text{hour}$ biotin hold, with immediate reinstatement of her $300\ \text{mg/day}$ dose post-phlebotomy.[1]

- **Quantitative Metabolic Profiling:** Obtain a quantitative urine organic acid and acylglycine profile via GC-MS and a plasma acylcarnitine profile via LC-MS/MS to identify any elevations of β-hydroxyisovaleric acid, β-methylcrotonylglycine, or propionylcarnitine.[1] This will confirm whether her current biotin dose of $300\ \text{mg/day}$ is biochemically sufficient to normalize her carboxylase enzyme functions.[1]
- **Comprehensive Audiological Screening:** Perform pure-tone audiometry and brainstem auditory evoked responses (BAER) to screen for subclinical sensorineural hearing loss, a recognized complication of biotinidase deficiency.[1]

Long-Term Surveillance Protocols and Red Flags

- **Specialized Neuro-Urology & Sphincter Rehabilitation:** Refer Sila to a specialized pediatric neuro-urologist to undergo conventional and imaging urodynamic studies.[61] This is essential to characterize her bladder dysfunction and guide a structured program (such as timed voiding or clean intermittent catheterization).[62] Once her diagnostic status is fully established, evaluate her candidacy for sacral neuromodulation (SNM) to treat her refractory bladder and bowel symptoms, noting its potential to achieve complete clinical "cure" and subsequent device explantation.[61]
- **Annual Specialist Surveillance:** Sila must undergo annual clinical genetics and metabolic specialist evaluations, alongside annual ophthalmological and audiological surveillance, to monitor for progressive optic atrophy or sensorineural deficits.[7]
- **Radiological Alignment & Bone Density Tracking:** Standing scoliosis X-ray series must be performed every 6 to 12 months to monitor her paraspinal alignment.[1] Annual DEXA scans must be scheduled to track her bone density recovery and determine the duration of her bisphosphonate therapy.[31]
- **Educate Family on Critical Clinical Red Flags:** The family and care team must be trained to recognize acute clinical red flags that require immediate emergency evaluation and urgent contrast-enhanced cranio-spinal MRI:
  - Any new or progressive visual impairment, ocular pain exacerbated by eye movement, or positive visual phenomena (suggestive of bilateral optic pathway demyelinating relapse).[11]
  - Worsening lower extremity motor strength, ascending sensory loss, or a sudden change in bladder or bowel control.[1]
  - Any acute breathing difficulty, shortness of breath, or respiratory distress.[1] Because of her high-cervical and brainstem lesions, Sila remains at risk for diaphragmatic paralysis and central respiratory compromise, which can be life-threatening and require immediate mechanical respiratory support.[1]

Works cited

1. Clinical Strategic Review - Sila Khaled Attia.md
2. Biotinidase deficiency - Orphanet, accessed May 23, 2026, https://www.orpha.net/en/disease/detail/79241
3. BTD gene: MedlinePlus Genetics, accessed May 23, 2026, https://medlineplus.gov/genetics/gene/btd/
4. Biotinidase Deficiency | Revvity, accessed May 23, 2026, https://www.revvity.com/conditions-and-diseases/biotinidase-deficiency
5. Biotinidase deficiency - Patient.info, accessed May 23, 2026, https://patient.info/doctor/neurology/biotinidase-deficiency
6. Genetic Clinics, accessed May 23, 2026, http://iamg.in/genetic_clinics/full_textd08d.html?id=386
7. Biotinidase Deficiency - GeneReviews® - NCBI Bookshelf, accessed May 23, 2026, https://www.ncbi.nlm.nih.gov/books/NBK1322/
8. Clinical and molecular characterization of 14 Egyptian children with fructose-1,6-bisphosphatase deficiency - PMC, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12670856/
9. Clinical and biochemical spectrum of metabolic cardiomyopathy in Egyptian children, accessed May 23, 2026, https://pubmed.ncbi.nlm.nih.gov/36032483/
10. Osteoporosis/Low Bone Mineral Content in Children | PM&R KnowledgeNow - American Academy of Physical Medicine and Rehabilitation, accessed May 23, 2026, https://now.aapmr.org/osteoporosis-osteopenia-in-children/
11. (PDF) Neuromyelitis Optica (NMO) — Study Review - ResearchGate, accessed May 23, 2026, https://www.researchgate.net/publication/356198470_Neuromyelitis_Optica_NMO_-_Study_Review
12. REVIEWS - St George's Hospital, accessed May 23, 2026, https://www.stgeorges.nhs.uk/wp-content/uploads/2014/12/Treatment-of-neuromyelitis-optica-state-of-the-art-and-emerging-therapies.pdf
13. Emerging therapeutic targets for neuromyelitis optica spectrum disorders - PMC - NIH, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7941255/
14. A practical guide to the diagnosis and management of osteoporosis in childhood and adolescence - PMC, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10875302/
15. Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay - PMC, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11920744/
16. (PDF) Biotin interference with laboratory test results - ResearchGate, accessed May 23, 2026, https://www.researchgate.net/publication/387901056_Biotin_interference_with_laboratory_test_results
17. AACC Guidance Document on Biotin Interference in Laboratory Tests | myadlm.org, accessed May 23, 2026, https://myadlm.org/science-and-research/academy-guidance/biotin-interference-in-laboratory-tests
18. Biotin induced biochemical hyperthyroidism: a case report and review of the literature - PMC, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10304644/
19. Population pharmacokinetics of exogenous biotin and the relationship between biotin serum levels and in vitro immunoassay interference - Semantic Scholar, accessed May 23, 2026, https://pdfs.semanticscholar.org/ef3e/abc62dcda2836187c0ce104236f92bf69db6.pdf

20. Biotin and lab tests: Beauty supplement poses risks for pregnant women | Your Pregnancy Matters | UT Southwestern Medical Center, accessed May 23, 2026, https://utswmed.org/medblog/biotin-risks-postpartum-hair-loss/
21. How Much Biotin Can Affect Thyroid Tests: What to Know - Blue Horizon Blood Tests, accessed May 23, 2026, https://bluehorizonbloodtests.co.uk/blogs/thyroid-health/how-much-biotin-can-affect-thyroid-tests
22. How Long to Hold Biotin Before Thyroid Test? Expert Guide - Blue Horizon Blood Tests, accessed May 23, 2026, https://bluehorizonbloodtests.co.uk/blogs/thyroid-health/how-long-to-hold-biotin-before-thyroid-test
23. Assessment of biotin interference in thyroid function tests - PMC - NIH, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7478465/
24. Osteoporosis and Bone Fragility in Children - Endotext - NCBI Bookshelf - NIH, accessed May 23, 2026, https://www.ncbi.nlm.nih.gov/books/NBK593436/
25. Does Fasting Affect Thyroid Test? Expert Tips for Results - Blue Horizon Blood Tests, accessed May 23, 2026, https://bluehorizonbloodtests.co.uk/blogs/thyroid-health/does-fasting-affect-thyroid-test-results
26. How Much Biotin Affects Thyroid Tests: What You Need To Know, accessed May 23, 2026, https://bluehorizonbloodtests.co.uk/blogs/thyroid-health/how-much-biotin-affects-thyroid-tests-what-you-need-to-know
27. Aquaporin-4 Antibodies (NMO Antibodies) - Peterborough Pathology Services, accessed May 23, 2026, http://pch-pathlab.com/cms/?q=node/419
28. Biotin Interference in Clinical Immunoassays | Request PDF - ResearchGate, accessed May 23, 2026, https://www.researchgate.net/publication/326562703_Biotin_Interference_in_Clinical_Immunoassays
29. Biotinidase deficiency – Treatment – Overview of Information and Clinical Research, accessed May 23, 2026, https://clinicaltrials.eu/disease/biotinidase-deficiency/biotinidase-deficiency-treatment/
30. Bisphosphonate therapy in pediatric patients - PMC - NIH, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC4279811/
31. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents, accessed May 23, 2026, https://firstpediatrics-uoa.com/wp-content/uploads/2025/05/9.-consensus-for-the-use-of-BPs-in-children.pdf
32. Evaluating Bone Health in Egyptian Children with Forearm Fractures: A Case Control Study, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC5019920/
33. Scottish Paediatric & Adolescent Rheumatology Network Protocol for the administration of Pamidronate Infusions in paediatric - National Networks, accessed May 23, 2026, https://www.nn.nhs.scot/sparn//wp-content/uploads/sites/18/2021/05/Pamidronate-protocol.pdf
34. Zoledronic Acid - Medical Clinical Policy Bulletins - Aetna, accessed May 23, 2026, https://www.aetna.com/cpb/medical/data/500_599/0524.html
35. Bisphosphonate Therapy - Pediatric Endocrine Society, accessed May 23, 2026, https://pedsendo.org/patient-resource/pamidronate-and-zoledronic-acid-infusions/
36. Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents - PMC, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8255864/
37. Endocrinology - intravenous bisphosphonate therapy - Starship, accessed May 23, 2026,

https://starship.org.nz/guidelines/endocrinology-intravenous-bisphosphonate-therapy/
38. Effectiveness and safety of pamidronate treatment in nonambulatory children with low bone mineral density, accessed May 23, 2026, https://www.e-apem.org/upload/pdf/apem-2346028-014.pdf
39. Clemastine in remyelination and protection of neurons and skeletal ..., accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9827778/
40. The potential of repurposing clemastine to promote remyelination - Frontiers, accessed May 23, 2026, https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2025.1582902/full
41. Clemastine | MS Trust, accessed May 23, 2026, https://mstrust.org.uk/a-z/clemastine
42. Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy - UCSF Clinical Trials, accessed May 23, 2026, https://clinicaltrials.ucsf.edu/trial/NCT06065670
43. The potential of repurposing clemastine to promote remyelination - PMC - NIH, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12092462/
44. Clemastine Enhances Myelination, Delays Axonal Loss and Promotes Functional Recovery in Spinal Cord Injury - PMC, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8827101/
45. Clemastine fumarate promotes myelin repair in a nonhuman primate model of demyelination characterized by absent spontaneous remyelination | PNAS, accessed May 23, 2026, https://www.pnas.org/doi/10.1073/pnas.2520161123
46. Study Details | NCT05359653 | Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy | ClinicalTrials.gov, accessed May 23, 2026, https://clinicaltrials.gov/study/NCT05359653
47. The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy - PubMed, accessed May 23, 2026, https://pubmed.ncbi.nlm.nih.gov/41361285/
48. Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis - JCI, accessed May 23, 2026, https://www.jci.org/articles/view/183941
49. Spring 2026 Milestones in SCI Clinical Trials, accessed May 23, 2026, https://nascic.org/spring-2026-milestones-in-sci-clinical-trials/
50. NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury, accessed May 23, 2026, https://nervgen.com/nervgen-pharma-announces-first-subject-dosed-in-landmark-phase-1b-2a-clinical-trial-for-nvg-291-in-spinal-cord-injury/
51. NVG-291 – A New Hope - Wings for Life, accessed May 23, 2026, https://www.wingsforlife.com/us/latest/nvg-291-a-new-hope-us
52. A Placebo-Controlled Phase I Study of NVG-291 in Healthy Subjects, Targeting CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPσ) (S8.009) | Neurology, accessed May 23, 2026, https://www.neurology.org/doi/10.1212/WNL.98.18_supplement.1679
53. NVG-291 in Spinal Cord Injury Subjects | SCI Trials Finder, accessed May 23, 2026, https://scitrialsfinder.net/trials/NCT05965700
54. NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury, accessed May 23, 2026, https://nervgen.com/nervgen-pharma-on-track-to-complete-enrollment-deliver-data-

readout-in-phase-1b-2a-clinical-trial-for-nvg-291-in-spinal-cord-injury/
55. NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia, accessed May 23, 2026, https://nervgen.com/nervgen-pharma-announces-successful-end-of-phase-2-meeting-and-fda-alignment-on-restore-a-phase-3-registrational-study-of-nvg-291-for-chronic-tetraplegia/
56. NVG-291 in Spinal Cord Injury Subjects | Clinical Research Trial Listing - CenterWatch, accessed May 23, 2026, https://www.centerwatch.com/clinical-trials/listings/NCT05965700/nvg-291-in-spinal-cord-injury-subjects
57. Stem Cell Therapy for Spinal Cord Injury: A Review of Recent Clinical Trials - PMC - NIH, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9148387/
58. Stem Cell-Based Approaches for Spinal Cord Injury: The Promise of iPSCs - MDPI, accessed May 23, 2026, https://www.mdpi.com/2079-7737/14/3/314
59. Clinical Resources — International Society for Stem Cell Research - Isscr, accessed May 23, 2026, https://www.isscr.org/clinicians
60. Clinical Trials of Stem Cell Treatment for Spinal Cord Injury - PMC - NIH, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7313002/
61. Stratified dynamic analysis reveals postoperative recovery trajectories of sacral neuromodulation in pediatric neurogenic bladder - Frontiers, accessed May 23, 2026, https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2025.1582311/full
62. Evaluating the likelihood of pediatric sacral nerve stimulator explantations due to cure or complications: a survival analysis of 13-year institutional cohort - PMC, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12394247/
63. Understanding the Role of Neuromodulation in Neurogenic Bladder - American Urological Association - AUANews, accessed May 23, 2026, https://auanews.net/issues/articles/2026/april-2026/understanding-the-role-of-neuromodulation-in-neurogenic-bladder
64. Stem Cells Therapy for Spinal Cord Injury: An Overview of Clinical Trials - PMC - NIH, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7013533/
65. Nagia Fahmy - Google Scholar, accessed May 23, 2026, https://scholar.google.com/citations?user=NITLLk4AAAAJ&hl=en
66. Research and Treatment of Genetic Diseases Center, accessed May 23, 2026, https://www.asu.edu.eg/ce/84/page
67. Solaf Mohamed Elsayed professor of medical Genetics Professor (Full) at Ain Shams University - ResearchGate, accessed May 23, 2026, https://www.researchgate.net/profile/Solaf-Elsayed
68. Ain Shams University provides treatment for the first Egyptian child to receive the most expensive medicine in the world, with a value of EGP 34 million, accessed May 23, 2026, https://www.asu.edu.eg/1912/news/ain-shams-university-provides-treatment-for-the-first-egyptian-child-to-receive-the-most-expensive-medicine-in-the-world-with-a-value-of-egp-34-million
69. Osama K. Zaki MS human Genetics, MS Pediatrics,PhD Med Genetics Consultant Professor at Ain Shams University - ResearchGate, accessed May 23, 2026, https://www.researchgate.net/profile/Osama-Zaki
70. Nevine EL NAHAS | Professor | Doctor of Neurology | Ain Shams University, Cairo | neuropsyciatry | Research profile - ResearchGate, accessed May 23, 2026, https://www.researchgate.net/profile/Nevine-El-Nahas-2
71. Selective screening for inborn errors of metabolism by tandem mass spectrometry in Egyptian

children: a 5 year report - PubMed, accessed May 23, 2026, https://pubmed.ncbi.nlm.nih.gov/24731791/
72. Laila SELIM | Cairo University, Giza | CU | Department of Pediatrics | Research profile, accessed May 23, 2026, https://www.researchgate.net/profile/Laila-Selim
73. Laila SELIM | Cairo University, Giza | CU | Department of Pediatrics | Research profile, accessed May 23, 2026, https://www.researchgate.net/profile/Laila-Selim-2
74. Dr. Hasnaa Elbendary, Pediatrics, Egypt - DRAPP, accessed May 23, 2026, https://drapp.me/d/eg/pediatrics/dr-hasnaa-elbendary-8532
75. Ain Shams Hospital - Pediatrics Department, accessed May 23, 2026, http://pediatric.asu.edu.eg/hospital/en/
76. Best Sacral Neuromodulation Doctors in Egypt | Top Specialists - Vaidam Health, accessed May 23, 2026, https://www.vaidam.com/doctors/sacral-neuromodulation/egypt
77. Best Sacral Neuromodulation Hospitals in Egypt 2026 | MediJourney, accessed May 23, 2026, https://www.medijourney.co.in/hospitals/urology-2/sacral-neuromodulation/egypt
78. Genomic and Structural Investigation of Mutations in Biotinidase (BTD) Gene Deficiency in Greater Middle Eastern Cohort: Insights from Molecular Dynamics Study - PMC, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12467526/
79. Comparative genetic diagnostic evaluation of pediatric neuromuscular diseases in a consanguineous population - PubMed, accessed May 23, 2026, https://pubmed.ncbi.nlm.nih.gov/39747233/
80. Sacral neuromodulation in pediatric bladder and bowel dysfunctions: Literature review, accessed May 23, 2026, https://journals.eco-vector.com/turner/article/view/111919
81. Areeg Hassan El-Gharbawy, MD, DSc | Pediatric Medical Genetics Specialist | Duke Health, accessed May 23, 2026, https://www.dukehealth.org/find-doctors-physicians/areeg-hassan-el-gharbawy-md-dsc
82. Steroid Refractory and Plasma Exchange Partially Responsive Longitudinally Extensive Transverse Myelitis Due to Tumor Necrosis Factor-Alpha (Etanercept): A Case Report - MDPI, accessed May 23, 2026, https://www.mdpi.com/2039-7283/16/5/86
83. Developmental window of sensorineural deafness in biotinidase-deficient mice - PMC, accessed May 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8148422/